{"id":"menacyw-135-conjugate-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsules from four meningococcal serogroups conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent immune responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these four serogroups.","oneSentence":"MenACYW-135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:40.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135"}]},"trialDetails":[{"nctId":"NCT07135986","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-26","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":1602},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MENVEO®"],"phase":"phase_3","status":"active","brandName":"MenACYW-135 conjugate vaccine","genericName":"MenACYW-135 conjugate vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACYW-135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}